LGC forms "personalised" drug testing deal:
This article was originally published in Clinica
Executive Summary
UK genetic testing firm LGC has issued a testing licence to Orchid BioSciences for the key DNA variant in the CYP2D6 gene, which controls a drug metabolising enzyme in the human liver. Individuals with the gene mutation, around 6% of the Caucasian population, cannot correctly metabolise around 20% of currently prescribed medications, says Teddington, Middlesex-based LGC. Testing for the mutation may help predict a patient's response to various drugs and help them avoid serious adverse reactions.